These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 11098561)
1. [Therapeutic inhibition of platelets in a acute coronary syndrome and in coronary intervention: mechanisms and clinical results]. Peter K; Nordt T; Bode C Z Kardiol; 2000; 89 Suppl 7():60-9. PubMed ID: 11098561 [TBL] [Abstract][Full Text] [Related]
2. [Therapeutic inhibition of platelets in acute coronary syndrome and in coronary intervention: mechanisms and clinical results]. Peter K; Nordt T; Bode C Z Kardiol; 2000 Oct; 89(Suppl 7):60-9. PubMed ID: 27320527 [TBL] [Abstract][Full Text] [Related]
4. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease. Berkowitz SD Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626 [TBL] [Abstract][Full Text] [Related]
5. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173 [TBL] [Abstract][Full Text] [Related]
6. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Adgey AA Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518 [TBL] [Abstract][Full Text] [Related]
8. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379 [TBL] [Abstract][Full Text] [Related]
9. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519 [TBL] [Abstract][Full Text] [Related]
10. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention. Feldman DN; Wong SC; Bergman G; Minutello RM J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400 [TBL] [Abstract][Full Text] [Related]
11. [Impact of GP IIb/IIIa antagonists in interventional cardiology]. Scheller B; Hennen B; Böhm M; Nickenig G Dtsch Med Wochenschr; 2003 Feb; 128(6):281-7. PubMed ID: 12571800 [No Abstract] [Full Text] [Related]
13. Advancing the battle against acute ischemic syndromes: a focus on the GP IIb-IIIa inhibitors. Dobesh PP; Latham KA Pharmacotherapy; 1998; 18(4):663-85. PubMed ID: 9692642 [TBL] [Abstract][Full Text] [Related]
14. Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors. Roe MT; Moliterno DJ J Thromb Thrombolysis; 1999 Jun; 7(3):247-57. PubMed ID: 10373718 [No Abstract] [Full Text] [Related]
15. Platelet glycoprotein IIb/IIIa receptor blockade and coronary resistance in unstable angina. Marzilli M; Sambuceti G; Testa R; Fedele S J Am Coll Cardiol; 2002 Dec; 40(12):2102-9. PubMed ID: 12505220 [TBL] [Abstract][Full Text] [Related]
16. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466 [TBL] [Abstract][Full Text] [Related]
18. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034 [TBL] [Abstract][Full Text] [Related]
19. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty. Verdoia M; Pergolini P; Camaro C; Restifo M; Rolla R; Schaffer A; Di Giovine G; Marino P; Bellomo G; Suryapranata H; De Luca G; Blood Coagul Fibrinolysis; 2013 Jun; 24(4):411-8. PubMed ID: 23412353 [TBL] [Abstract][Full Text] [Related]
20. Antiplatelet therapy for ischemic heart disease. Lange RA; Hillis LD N Engl J Med; 2004 Jan; 350(3):277-80. PubMed ID: 14724308 [No Abstract] [Full Text] [Related] [Next] [New Search]